| Literature DB >> 27349891 |
Lin Yao1,2,3, Kunlin Yang1,2,3, Xuesong Li1,2,3, Zheng Zhang4,5,6, Cuijian Zhang1,2,3, Kan Gong1,2,3, Zhijun Xi1,2,3, Zhisong He1,2,3, Liqun Zhou7,8,9.
Abstract
BACKGROUND: To evaluate the safety and efficacy of the completely retroperitoneoscopic nephroureterectomy (CRNU), a retrospectively comparative study between completely and traditionally retroperitoneoscopic nephroureterectomy (TRNU) was done in a single center.Entities:
Keywords: Retroperitoneal; Retroperitoneoscopic nephroureterectomy; Upper tract urothelial cancer
Mesh:
Year: 2016 PMID: 27349891 PMCID: PMC4924241 DOI: 10.1186/s12957-016-0924-3
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Trocar distribution and change of operative position (affected side is on the right in this example). a, b Point a: 2 cm below the crossing point of the posterior axillary line and the 12th rib margin. Point b: 3 cm ventrally to the crossing point of the midaxillary line and iliac crest. Point c: 2 cm below the costal margin in the anterior axillary line. Point d: at the McBurney’s point. c, d The positions of the television monitor, surgeon, and assistant when nephrectomy with mobilization of the proximal ureter and when distal ureterectomy with bladder cuff excision. R right, L left, S surgeon, A assistant
Fig. 2Operative view of main surgical steps. u ureter, k kidney, v renal vein, a renal artery. a Nephrectomy and mobilization of proximal ureter. The ureter is clamped by Hem-o-lok. b Distal ureter is dissected in the pelvic cavity. c Distal ureter with the bladder cuff marked with black dotted line. d The cutting margin of the required bladder cuff marked with yellow dotted line. e The bladder cuff is cut by endoscopic gastrointestinal automatic stapler. f The cutting margin of the required bladder cuff marked with yellow dotted line
Fig. 3The healed bladder incision marked with the red arrow is no ureteral orifice on the affected side when under cystoscopy examination 3 months after surgery
Patient’s characteristics, surgical results, and follow-up outcomes of CRNU and TRNU
| Parameter | CRNU | TRNU |
|
|---|---|---|---|
| No. patients, | 107 | 110 | |
| Sex | 0.91 | ||
| Male | 46 | 48 | |
| Female | 61 | 62 | |
| Median age, year (range) | 71 (55–82) | 71 (52–88) | 0.51 |
| Mean BMI, kg/m2 (range; ±SD) | 23.2 (18.1–28.1; ±2.8) | 23.5 (17.6–29; ±2.9) | 0.50 |
| Operative side, | 0.71 | ||
| Left | 52 | 51 | |
| Right | 55 | 59 | |
| Tumor location | |||
| Renal pelvis | 62 | 68 | |
| Ureter | 39 | 37 | |
| Upper | 21 | 18 | |
| Mid | 4 | 10 | |
| Distal | 14 | 9 | |
| Multiple location | 6 | 5 | |
| Mean overall operating time, min (range; ±SD) | 106.0 (46–216; ±37.9) | 199.5 (100–416; ±69.1) | <0.0001 |
| Male | 105.0 (76–172; ±25.7) | 218.3 (128–416; ±71.9) | <0.0001 |
|
| 0.93 > 0.05 | 0.06 > 0.05 | |
| Female | 106.5 (46–216; ±42.3) | 185.1 (100–410; ±63.2) | <0.0001 |
| Mean estimated blood loss, ml (range; ±SD) | 47.2 (5–400; ±82.4) | 166.9 (20–1450; ±250.9) | 0.002 |
| RNU with lymph node dissection | |||
| No. of patients | 3 | No | |
| Open conversion | No | No | |
| Intraoperative and postoperative complications | |||
| (n/Clavien Classification) | |||
| UTI | 4/grade II | 7/grade II | |
| Lymphatic leakage | 4/grade I | 2/grade I | |
| Others | 0 | 0 | |
| Single bladder instillation of chemotherapy | 95 | 97 | |
| The removal time of drain after surgery, days (range; ± SD) | 4.0 (2–17; ±3.0) | 4.2 (2–12; ±1.5) | 0.79 |
| Mean hospital stay, days (range; ±SD) | 6.1 (3–21; ±3.5) | 8.1 (4–26; ±3.3) | 0.03 |
| The removal time of urethral catheter after surgery, week | 1 | 1 | |
| Pathologic stage, | |||
| pTaN0M0 | 8 | 6 | |
| pT1N0M0 | 63 | 65 | |
| pT1N1M0 | 0 | 1 | |
| pT2N0M0 | 30 | 23 | |
| pT2N2M0 | 1 | 0 | |
| pT3N0M0 | 4 | 14 | |
| pT3N1M0 | 1 | 0 | |
| pT4N2M0 | 0 | 1 | |
| Pathologic grade (G), | |||
| G1 | 38 | 31 | |
| G2 | 54 | 52 | |
| G3 | 15 | 27 | |
| The surgical margin of the distal ureter (negative or positive) | Negative | Negative | |
| Mean follow-up time, month (range; ±SD) | 13.4 (6–18; ±2.1) | 37.5 (13–63; ±15.9) | |
| No. of patients of follow-up ( | 105 | 106 | |
| Bladder tumor recurrence | |||
| No. patients of follow-up ( | 4 | 21 |
BMI body mass index, CRNU completely retroperitoneoscopic nephroureterectomy, TRNU traditionally retroperitoneoscopic nephroureterectomy, UTI urinary tract infection